Panagiotis Christoforou: Proud to Contribute to Barts Health’s Leading Role in UK Clinical Trials
Panagiotis Christoforou, Senior Research Fellow at Barts Health NHS Trust, shared Barts Health NHS Trust’s post on LinkedIn:
“Proud, as a Haematologist, to have been part of this achievement and to have contributed as a Clinical Research Fellow to Non-malignant haematology clinical trials at the Royal London Hospital.
It has been a privilege to work alongside such a dedicated multidisciplinary team, helping bring innovative treatments and new opportunities to our patients.”
Barts Health NHS Trust shared a post on LinkedIn:
“We’re the UK’s top recruiter to clinical trials.
More than 20,000 patients took part in research across our hospitals last year, helping advance healthcare for future generations.
For the seventh year running, we’ve recruited more patients to commercial drug trials than any other NHS trust, giving patients access to pioneering treatments and the latest innovations in care.
It’s all part of our commitment to delivering outstanding patient care through research, innovation and clinical excellence”
Other posts featuring Panagiotis Christoforou on Hemostasis Today.
-
Sep 5, 2026, 04:16Key Cardiovascular Insights from ESC Congress
-
Sep 5, 2026, 03:30Rob Maloney: Who Are the Real Experts? – The Quiet Resilience of the Bleeding Disorders Community
-
Sep 5, 2026, 03:26Project Elevate Her – Scaling Heights for Bleeding Disorders Awareness – WFH
-
Sep 5, 2026, 03:20Sarah Bassiony: How Do non-Specialists Learn Haematology? – Participate in Our Remote Study
-
Sep 5, 2026, 03:13Omid Seidizadeh: Uncovering the Genetic Architecture of Low Von Willebrand Factor
-
Sep 5, 2026, 03:07Luke McLaughlin: The First Community Article of the Haemophilia Rights Project
-
Sep 5, 2026, 02:51Kassiani Maria Nastouli: Honored to Be Cited in the New ESC Guidelines on the Management of CVD and CKD
-
Sep 5, 2026, 02:44Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
-
Sep 5, 2026, 02:35Balaji Balagani: Exploring Stable vs Unstable vs Complete Coronary Block